Description

West Pharmaceutical Services: Demand Is Outrunning Supply—Can Capacity Investments Close the Gap?

West Pharmaceutical Services reported its financial results for the fourth quarter and full year of 2025, showcasing a period of growth and strategic execution. The company achieved significant milestones, including surpassing $3 billion in net sales with organic growth of over 4% year-over-year, expanding operating margins, and achieving an 8% growth in adjusted earnings per share (EPS). The fourth quarter revenues were $805 million, a 7.5% increase year-over-year, exceeding expectations along with a 12% rise in adjusted EPS to $2.04. The growth was primarily driven by the company’s High-Value Product (HVP) components business, which accounted for a significant portion of the revenue increase, reflecting the company’s strong market position in biologics and regulatory-driven market demands such as Annex 1 compliance and growth in the GLP-1 market.